CA2389012A1 - Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial - Google Patents

Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial Download PDF

Info

Publication number
CA2389012A1
CA2389012A1 CA002389012A CA2389012A CA2389012A1 CA 2389012 A1 CA2389012 A1 CA 2389012A1 CA 002389012 A CA002389012 A CA 002389012A CA 2389012 A CA2389012 A CA 2389012A CA 2389012 A1 CA2389012 A1 CA 2389012A1
Authority
CA
Canada
Prior art keywords
compound
sodium
dimethoxyphenyl
ethoxy
diphenylpropionate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389012A
Other languages
English (en)
Inventor
Rolf Jansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2389012A1 publication Critical patent/CA2389012A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne le composé de la formule sous forme cristalline, notamment l'énantiomère-S, ainsi que son utilisation comme antagonistes de récepteur d'endothéline ET¿A?/ET¿B?- mélangés.
CA002389012A 1999-10-27 2000-10-17 Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial Abandoned CA2389012A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19951671A DE19951671A1 (de) 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist
DE19951671.5 1999-10-27
PCT/EP2000/010202 WO2001030767A1 (fr) 1999-10-27 2000-10-17 Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial

Publications (1)

Publication Number Publication Date
CA2389012A1 true CA2389012A1 (fr) 2001-05-03

Family

ID=7927001

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389012A Abandoned CA2389012A1 (fr) 1999-10-27 2000-10-17 Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial

Country Status (17)

Country Link
EP (1) EP1228047A1 (fr)
JP (1) JP2003512460A (fr)
KR (1) KR20020047301A (fr)
CN (1) CN1384822A (fr)
AU (1) AU1272701A (fr)
BG (1) BG106700A (fr)
BR (1) BR0015112A (fr)
CA (1) CA2389012A1 (fr)
CZ (1) CZ20021485A3 (fr)
DE (1) DE19951671A1 (fr)
HU (1) HUP0203476A3 (fr)
IL (1) IL149312A0 (fr)
MX (1) MXPA02004071A (fr)
NO (1) NO20021986D0 (fr)
SK (1) SK5962002A3 (fr)
TR (1) TR200201169T2 (fr)
WO (1) WO2001030767A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101006076B (zh) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
NO20021986L (no) 2002-04-26
BR0015112A (pt) 2002-10-29
JP2003512460A (ja) 2003-04-02
KR20020047301A (ko) 2002-06-21
NO20021986D0 (no) 2002-04-26
HUP0203476A2 (en) 2003-05-28
BG106700A (en) 2003-02-28
HUP0203476A3 (en) 2003-07-28
MXPA02004071A (es) 2002-10-11
WO2001030767A1 (fr) 2001-05-03
DE19951671A1 (de) 2001-05-03
TR200201169T2 (tr) 2002-09-23
IL149312A0 (en) 2002-11-10
AU1272701A (en) 2001-05-08
CZ20021485A3 (cs) 2003-06-18
SK5962002A3 (en) 2002-09-10
CN1384822A (zh) 2002-12-11
EP1228047A1 (fr) 2002-08-07

Similar Documents

Publication Publication Date Title
CN101184734B (zh) 治疗细胞增殖紊乱的化合物和方法
JP4086316B2 (ja) ブラジキニン受容体親和性を有する新規ｎ―（アリールスルホニル）アミノ酸誘導体
US7691894B2 (en) Cyclohexanecarboxylic acid compound
JP2002504916A (ja) 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
CA2155307A1 (fr) Composes heterocycliques, inhibiteurs de l'agregation des plaquettes
NO152972B (no) Analogifremgangsmaate for fremstilling av 2-(1-fenylbenzimidazolyl)-acetohydroksamsyre med terapeutisk aktivitet
NO170883B (no) Fremgangsmaate for fremstilling av 2-amino-5-hydroksy-4-metylpyrimidin-derivater
WO2000061556A1 (fr) Composes heterocycliques contenant de l'azote et composes de benamide et medicaments contenant ces composes
EP2294056A1 (fr) Sels de bosentan
JP2001513767A (ja) メタロプロテアーゼ阻害剤としての逆ヒドロキサメート誘導体
FR2883285A1 (fr) Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique
SK4592000A3 (en) Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists
CA2389012A1 (fr) Sel de potassium d'acide 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionique et son utilisation comme antagoniste endothelial
JPH10316647A (ja) グアニジン誘導体およびその用途
US3822262A (en) Phenyl acetylimino-imidazolines and-hexahydropyrimidines
MXPA02000033A (es) Polimorfos de un diclorhidrato cristalino de azobiciclo (2, 2, 2)oct-3-ilamina y sus composiciones farmaceuticas.
JP4871273B2 (ja) ４−トリフルオロメトキシフェノキシベンゾール−４’−スルホン酸、その製造法および薬剤としての使用
JP3262794B2 (ja) アミノアルキル置換された５−メルカプトチアゾール、その製造及び使用
RU2335494C2 (ru) Производные бициклических иминокислот в качестве ингибиторов матриксных металлопротеиназ
MXPA02010593A (es) Inhibidores de uroquinasa de naftamidina.
US4113877A (en) Substituted 2-aminomethylphenyl sulfamates
AU2006207701B2 (en) Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases
CA1299180C (fr) 4-(arylcarbonyl)-1-[(morpholin-4-yl)alkyl inferieur]-1h-indoles
GB1573066A (en) Piperidylureas and thioreas
CN118063489A (zh) 吴茱萸碱类化合物及其制药用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued